Filtern
Volltext vorhanden
- ja (3)
Gehört zur Bibliographie
- ja (3)
Dokumenttyp
Sprache
- Englisch (3)
Schlagworte
- Active disease (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Acute myeloid leukemia (AML) (1)
- Allogeneic transplantation (1)
- Bone marrow transplantation (1)
- Cancer risk factors (1)
- Chronic lymphoblastic leukemia (1)
- Chronic myeloid leukemia (1)
- Conditioning regimen (1)
- Fludarabine (1)
- Fludarabine-treosulfan (FT) (1)
- HLA-E matching (1)
- HSTC outcome (1)
- Hematopoietic stem cell transplantation (1)
- Immune receptor signaling (1)
- Killer cell immunoglobulin-like receptors (1)
- Multivariate analysis (1)
- NK-cells (1)
- Sibling donor (MSD) (1)
- Stem cell transplantation (1)
- T-cells (1)
- Thiotepa-busulfan-fludarabine (TBF) (1)
- Unrelated donor (UD) (1)
- acute leukemia (AL) (1)
- amsacrine (1)
- cyclophosphamide (FLAMSA) (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- human leukocyte antigen-E (HLA-E) (1)
- intermediate dose Ara-C (1)
- medicine (1)
- total body irradiation/busulfan (1)
Institut
The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)=0.63, confidence interval (CI) 95%=0.48–0.83, P=0.001) analyses. Further subgroup analysis demonstrated that the positive effect of HLA-E mismatch was significant and pronounced in advanced disease patients (n=120) (5-year OS: 50% vs. 18%, P=0.005; HR=0.40, CI 95%=0.22–0.72, P=0.002; results from univariate and multivariate analyses, respectively). The study herein is the first to report an association between HLA-E incompatibility and improved post–transplant prognosis in AL patients who have undergone matched unrelated HSCT. Combined NK and T cell HLA-E-mediated mechanisms may account for the better outcomes observed. Notwithstanding the necessity for in vitro and confirmational studies, our findings highlight the clinical relevance of HLA-E matching and strongly support prospective HLA-E screening upon donor selection for matched AL unrelated HSCTs.